Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Emergent Biosolutions Inc (NYSE: EBS) was $11.05 for the day, up 0.91% from the previous closing price of $10.95. In other words, the price has increased by $0.91 from its previous closing price. On the day, 0.62 million shares were traded. EBS stock price reached its highest trading level at $11.1791 during the session, while it also had its lowest trading level at $10.772.
Ratios:
Our analysis of EBS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 414.54. For the most recent quarter (mrq), Quick Ratio is recorded 3.15 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.15.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On August 22, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16.
The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 10 ’25 when DeGolyer Donald W sold 17,801 shares for $10.54 per share. The transaction valued at 187,623 led to the insider holds 119,858 shares of the business.
Dayal Sujata Tyagi sold 8,552 shares of EBS for $85,520 on Nov 07 ’25. The Director now owns 88,980 shares after completing the transaction at $10.00 per share. On Nov 10 ’25, another insider, DONALD DEGOLYER, who serves as the Director of the company, bought 17,801 shares for $10.54 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 589529664 and an Enterprise Value of 1005845632. As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 8.54. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.74 while its Price-to-Book (P/B) ratio in mrq is 1.00. Its current Enterprise Value per Revenue stands at 1.275 whereas that against EBITDA is 4.572.
Stock Price History:
The Beta on a monthly basis for EBS is 2.33, which has changed by 0.09189725 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $13.41, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 13.49%, while the 200-Day Moving Average is calculated to be 49.45%.
Shares Statistics:
EBS traded an average of 1.11M shares per day over the past three months and 926520 shares per day over the past ten days. A total of 52.70M shares are outstanding, with a floating share count of 50.44M. Insiders hold about 3.95% of the company’s shares, while institutions hold 79.63% stake in the company. Shares short for EBS as of 1763078400 were 9260505 with a Short Ratio of 8.33, compared to 1760486400 on 8830216. Therefore, it implies a Short% of Shares Outstanding of 9260505 and a Short% of Float of 17.819999.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.97, with high estimates of $0.97 and low estimates of $0.97.
Analysts are recommending an EPS of between $2.05 and $2.05 for the fiscal current year, implying an average EPS of $2.05. EPS for the following year is $4.02, with 1.0 analysts recommending between $4.02 and $4.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 2 analysts. It ranges from a high estimate of $220M to a low estimate of $215M. As of. The current estimate, Emergent Biosolutions Inc’s year-ago sales were $194.7MFor the next quarter, 2 analysts are estimating revenue of $275M. There is a high estimate of $275M for the next quarter, whereas the lowest estimate is $275M.
A total of 2 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $809.6M, while the lowest revenue estimate was $809.2M, resulting in an average revenue estimate of $809.4M. In the same quarter a year ago, actual revenue was $1.04BBased on 1 analysts’ estimates, the company’s revenue will be $1.16B in the next fiscal year. The high estimate is $1.16B and the low estimate is $1.16B.
